Evidence map›Paper›PMID 40156168›Full record

ArticleJournal of the International AIDS Society2025

PrEP use and willingness cascades among GBMSM in 15 Asian countries/territories: an analysis of the PrEP APPEAL survey.

Gede Benny Setia Wirawan, Heather-Marie Schimdt, Curtis Chan, Doug Fraser, Jason J Ong, Michael Cassell, Lei Zhang, Warittha Tieosapjaroen, Nittaya Phanuphak, Weiming Tang and 4 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Gede Benny Setia WirawanKirby Institute, UNSW, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-0477-5749
Heather-Marie SchimdtJoint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland.ORCID https://orcid.org/0000-0002-2629-6407
Curtis ChanKirby Institute, UNSW, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-9581-1011
Doug FraserKirby Institute, UNSW, Sydney, New South Wales, Australia.
Jason J OngSchool of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Michael CassellFHI 360, Hanoi, Vietnam.
Lei ZhangSchool of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Warittha TieosapjaroenSchool of Translational Medicine, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-9712-9262
Nittaya PhanuphakInstitute of HIV Research and Innovation (IHRI), Bangkok, Thailand.ORCID https://orcid.org/0000-0002-0036-3165
Weiming TangSocial Entrepreneurship to Spur Health Global, Guangzhou, China.ORCID https://orcid.org/0000-0002-9026-707X
Nicky SuwandiAsia-Pacific Coalition on Male Sexual Health, Bangkok, Thailand.
Kimberly A GreenPATH, Primary Health Care, Seattle, Washington, USA.
Timothy DobbinsSchool of Population Health, UNSW, Sydney, New South Wales, Australia.
Benjamin R BavintonKirby Institute, UNSW, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-5834-8278

Funding

Kirby InstituteMAC AIDS FundNSW Ministry of HealthOutstanding Young Scholars Support ProgramOutstanding Young Scholar Support Programthe Australian Government Department of HealthViiV HealthcareWorld Health Organization 001
6 · The paper itself

Abstract

introductionDespite the high HIV incidence among gay, bisexual and other men who have sex with men (GBMSM) and the demonstrated effectiveness of HIV pre-exposure prophylaxis (PrEP), PrEP is not accessible at scale across Asia. To help inform future scaling efforts, our study aimed to examine PrEP use and willingness to use among GBMSM to identify opportunities and target groups for upscaling PrEP.

methodsThe PrEP APPEAL survey was a cross-sectional survey, promoted through online advertising and community organizations, from May to November 2022. Eligible participants were adult GBMSM who self-identified as HIV negative residing in Asia. We constructed two cascades: PrEP use (comprising awareness, lifetime use and current use of PrEP) and PrEP willingness among participants who were aware of PrEP but had never used it (comprising HIV exposure risk, willingness in PrEP and willingness to pay for PrEP). Multivariable logistic regression models identified factors associated with lifetime PrEP use and PrEP willingness.

resultsOf 15,339 participants, 1440 were excluded due to missing data, leaving 13,899 for analysis. Most lived in large or capital cities (68.3%) and in lower-middle-income countries (45.1%). The median age was 30 (25-36) years old. For the PrEP use cascade, 82.2% (n = 11,427/13,899) of participants were aware of PrEP, 35.0% (n = 4000/11,427) had used it before and 70.1% (n = 2803/4000) of them were currently on PrEP. For the PrEP willingness cascade, 54.8% of (n = 4068/7427) PrEP-naïve participants engaged in one or more behaviours with a higher risk of HIV acquisition, 73.7% (n = 2996/4068) of them expressed willingness to use PrEP and 83.0% (n = 2487/2996) of them were willing to pay for PrEP. Multivariable logistic regression models identified system-level (PrEP availability, accessibility and affordability) predictors of PrEP use. Individual-level behaviours associated with higher HIV acquisition risks were associated with PrEP use and willingness.

conclusionsWhile PrEP uptake was suboptimal, there was high awareness and willingness in PrEP among GBMSM. This is encouraging for future scale-up efforts. Future PrEP programmes should address system-level barriers to support PrEP uptake.

Indexed as

Anti-HIV AgentsHIV InfectionsHomosexuality, MalePatient Acceptance of Health CarePre-Exposure ProphylaxisSexual and Gender MinoritiesAdolescentAdultAsiaCross-Sectional StudiesHealth Knowledge, Attitudes, PracticeHumansMaleMiddle AgedSurveys and QuestionnairesYoung AdultAnti-HIV AgentsAsiacascadeHIVHIV preventionmen who have sex with menpre‐exposure prophylaxis

Identifiers

PMID40156168
PMCPMC11953173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.